ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO739

Immunophenotypic Abnormalities of Uremic Patients Undergoing Peritoneal Dialysis

Session Information

  • Peritoneal Dialysis - II
    November 04, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Dialysis

  • 608 Peritoneal Dialysis

Authors

  • Molina, Maria, Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain
  • Yuste, Claudia, Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain
  • Morales, Enrique, Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain
  • Praga, Manuel, Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain
Background

Chronic kidney disease (CKD) is usually associated with various immunologic abnormalities. However, there is a scarcely data regarding the impact of peritoneal dialysis (PD) on these abnormalities.

Methods

We presented a descriptive transversal study analysing lymphocyte absolute counts and subpopulations (CD3+, CD4+, CD8+, CD56+, CD19+, and CD4+/CD8+) in patients undergoing PD. Those patients where compared with a similar cohort of haemodialysis (HD) patients.

Results

Nineteen PD patients were studied (mean time on PD 7.6 ± 6.57 [3-20] months, age 48.4 ±18.7 [22,80] years, 57.9% women, 10 % diabetics, mean weekly KTV 2.52 ± 0.43 [2.24, 2.82]). Fourteen patients started PD after a follow up in low clearance clinic, whereas 4 where transferred from HD (mean time on HD 5.5 ±4.1 [2,14] months) and one patient had a previous kidney transplant. Eleven patients (57.9%) presented absolute lymphopenia (<1200 cells/mm3), where 63.2% had a low CD3+ account (<850 cells /mm3), 42.1% low CD4+ (<500 cells/mm3), 15.8% low CD8+ (<160 cells /mm3), 21.1% low CD56+ (<60 cells /mm3) and 36.8% low CD19+ (<100 cells /mm3). Patients on continuous ambulatory PD (n=6) seem to have lower lymphocyte absolute counts compared with patients on automated PD (n=13) (1163 [927-1498] cells /mm3 vs 1074 [859-1271] cells /mm3 respectively], secondary to a lower lymphocyte subpopulations. Lymphopenia seem to be more frequent in patients with longer mean time on PD (mean time on PD on lymphopenics 7 [1-19] months vs 4 [3-7.2] non-lymphopenic, NS). When we compared PD with HD patients, PD patients presented a non-significant trend to low lymphocyte account secondary to CD3+, CD4+ and CD8+. However, PD patients could present less changes on CD19+, known for its atherogenic role.

Conclusion

PD patients presented several changes on them immune mediators that could be different from the observed alterations on HD patients that should be studied with larger studies. The different immunological profile could explain the best survival on PD patients.